Novel antineoplastics targeting genetic changes in colorectal cancer

Jamal Joudeh, Joshua E. Allen, Avisnata Das, Varun Prabhu, Michael Farbaniec, Jeffrey Adler, Wafik S. El-Deiry

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Cytotoxic chemotherapy remains the mainstay of the medical management of colorectal cancer (CRC). Research over the last two decades has led to a molecular understanding of the oncogenic mechanisms involved in CRC and has contributed to the rational development of antineoplastics that target these mechanisms. During carcinogenesis, genetic changes often occur in molecules that play key functional roles in cancer such as cell proliferation, angiogenesis, apoptosis, cell death and immune-mediated destruction of cancer cells. Here, we review novel antineoplastics that are approved or in development for CRC that target molecules associated with genetic aberrations in CRC. Some of these targeted antineoplastics have proven effective against other solid tumors and hold promise in treating CRC whereas others are now routinely used in combination with cytotoxic agents. This article reviews antineoplastics that target genetic changes in CRC, their antitumor mechanisms, and their stage of development.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
EditorsWafik El-Deiry
Pages1-34
Number of pages34
DOIs
StatePublished - Feb 15 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

Fingerprint

Antineoplastic Agents
Colorectal Neoplasms
Molecules
Chemotherapy
Cytotoxins
Cell proliferation
Cell death
Aberrations
Tumors
Neoplasms
Cells
Apoptosis
Carcinogenesis
Cell Death
Cell Proliferation
Drug Therapy
Research

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Joudeh, J., Allen, J. E., Das, A., Prabhu, V., Farbaniec, M., Adler, J., & El-Deiry, W. S. (2013). Novel antineoplastics targeting genetic changes in colorectal cancer. In W. El-Deiry (Ed.), Impact of Genetic Targets on Cancer Therapy (pp. 1-34). (Advances in Experimental Medicine and Biology; Vol. 779). https://doi.org/10.1007/978-1-4614-6176-0-1
Joudeh, Jamal ; Allen, Joshua E. ; Das, Avisnata ; Prabhu, Varun ; Farbaniec, Michael ; Adler, Jeffrey ; El-Deiry, Wafik S. / Novel antineoplastics targeting genetic changes in colorectal cancer. Impact of Genetic Targets on Cancer Therapy. editor / Wafik El-Deiry. 2013. pp. 1-34 (Advances in Experimental Medicine and Biology).
@inbook{2c01a39c8ed744e187c787179552dda9,
title = "Novel antineoplastics targeting genetic changes in colorectal cancer",
abstract = "Cytotoxic chemotherapy remains the mainstay of the medical management of colorectal cancer (CRC). Research over the last two decades has led to a molecular understanding of the oncogenic mechanisms involved in CRC and has contributed to the rational development of antineoplastics that target these mechanisms. During carcinogenesis, genetic changes often occur in molecules that play key functional roles in cancer such as cell proliferation, angiogenesis, apoptosis, cell death and immune-mediated destruction of cancer cells. Here, we review novel antineoplastics that are approved or in development for CRC that target molecules associated with genetic aberrations in CRC. Some of these targeted antineoplastics have proven effective against other solid tumors and hold promise in treating CRC whereas others are now routinely used in combination with cytotoxic agents. This article reviews antineoplastics that target genetic changes in CRC, their antitumor mechanisms, and their stage of development.",
author = "Jamal Joudeh and Allen, {Joshua E.} and Avisnata Das and Varun Prabhu and Michael Farbaniec and Jeffrey Adler and El-Deiry, {Wafik S.}",
year = "2013",
month = "2",
day = "15",
doi = "10.1007/978-1-4614-6176-0-1",
language = "English (US)",
isbn = "9781461461753",
series = "Advances in Experimental Medicine and Biology",
pages = "1--34",
editor = "Wafik El-Deiry",
booktitle = "Impact of Genetic Targets on Cancer Therapy",

}

Joudeh, J, Allen, JE, Das, A, Prabhu, V, Farbaniec, M, Adler, J & El-Deiry, WS 2013, Novel antineoplastics targeting genetic changes in colorectal cancer. in W El-Deiry (ed.), Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, vol. 779, pp. 1-34. https://doi.org/10.1007/978-1-4614-6176-0-1

Novel antineoplastics targeting genetic changes in colorectal cancer. / Joudeh, Jamal; Allen, Joshua E.; Das, Avisnata; Prabhu, Varun; Farbaniec, Michael; Adler, Jeffrey; El-Deiry, Wafik S.

Impact of Genetic Targets on Cancer Therapy. ed. / Wafik El-Deiry. 2013. p. 1-34 (Advances in Experimental Medicine and Biology; Vol. 779).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Novel antineoplastics targeting genetic changes in colorectal cancer

AU - Joudeh, Jamal

AU - Allen, Joshua E.

AU - Das, Avisnata

AU - Prabhu, Varun

AU - Farbaniec, Michael

AU - Adler, Jeffrey

AU - El-Deiry, Wafik S.

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Cytotoxic chemotherapy remains the mainstay of the medical management of colorectal cancer (CRC). Research over the last two decades has led to a molecular understanding of the oncogenic mechanisms involved in CRC and has contributed to the rational development of antineoplastics that target these mechanisms. During carcinogenesis, genetic changes often occur in molecules that play key functional roles in cancer such as cell proliferation, angiogenesis, apoptosis, cell death and immune-mediated destruction of cancer cells. Here, we review novel antineoplastics that are approved or in development for CRC that target molecules associated with genetic aberrations in CRC. Some of these targeted antineoplastics have proven effective against other solid tumors and hold promise in treating CRC whereas others are now routinely used in combination with cytotoxic agents. This article reviews antineoplastics that target genetic changes in CRC, their antitumor mechanisms, and their stage of development.

AB - Cytotoxic chemotherapy remains the mainstay of the medical management of colorectal cancer (CRC). Research over the last two decades has led to a molecular understanding of the oncogenic mechanisms involved in CRC and has contributed to the rational development of antineoplastics that target these mechanisms. During carcinogenesis, genetic changes often occur in molecules that play key functional roles in cancer such as cell proliferation, angiogenesis, apoptosis, cell death and immune-mediated destruction of cancer cells. Here, we review novel antineoplastics that are approved or in development for CRC that target molecules associated with genetic aberrations in CRC. Some of these targeted antineoplastics have proven effective against other solid tumors and hold promise in treating CRC whereas others are now routinely used in combination with cytotoxic agents. This article reviews antineoplastics that target genetic changes in CRC, their antitumor mechanisms, and their stage of development.

UR - http://www.scopus.com/inward/record.url?scp=84873592803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873592803&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-6176-0-1

DO - 10.1007/978-1-4614-6176-0-1

M3 - Chapter

C2 - 23288633

AN - SCOPUS:84873592803

SN - 9781461461753

T3 - Advances in Experimental Medicine and Biology

SP - 1

EP - 34

BT - Impact of Genetic Targets on Cancer Therapy

A2 - El-Deiry, Wafik

ER -

Joudeh J, Allen JE, Das A, Prabhu V, Farbaniec M, Adler J et al. Novel antineoplastics targeting genetic changes in colorectal cancer. In El-Deiry W, editor, Impact of Genetic Targets on Cancer Therapy. 2013. p. 1-34. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-6176-0-1